Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation.
Velusetrag (TD-5108) is a potent, selective high intrinsic activity serotonin 5-HT(4) receptor agonist. We assessed effects of Velusetrag on gastrointestinal transit and compared its pharmacokinetics in healthy volunteers (HV) and chronic constipation (CC) patients. Sixty HV were randomly assigned, double-blind to placebo, 5, 15, 30 or 50 mg Velusetrag (single and 6-day dosing). Primary endpoints were colonic transit (geometric centre at 24 h, GC24) and ascending colon emptying (ACE) T(1/2) after first dose. Secondary endpoints included gastric emptying (GE) T(1/2) and colonic filling at 6 h (CF6). Single dose Velusetrag significantly accelerated GC24, ACE T(1/2), and CF6; 30 and 50 mg Velusetrag accelerated all three endpoints. With multiple doses, Velusetrag 30 mg accelerated GC24, and overall accelerated GE T(1/2) at 15-50 mg. Pharmacokinetics studies showed dose proportionality in health, and no significant differences between health and chronic constipation with a 15 mg oral dose of Velusetrag. Stimulation of bowel function after15 mg Velusetrag was similar in CC and controls. There were no serious adverse events; notable adverse events were the predictable gastrointestinal effects such as diarrhoea or altered bowel movements. Velusetrag significantly accelerated intestinal and colonic transit after single dosing and accelerated gastric emptying after multiple dosing. Further studies of its potential as a gastrointestinal and colonic prokinetic are warranted.
Manini
M L
ML
Clinical Enteric Neuroscience Translational and Epidemiological Research, College of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Camilleri
M
M
Goldberg
M
M
Sweetser
S
S
McKinzie
S
S
Burton
D
D
Wong
S
S
Kitt
M M
MM
Li
Y-P
YP
Zinsmeister
A R
AR
D000293:Adolescent; D000328:Adult; D000368:Aged; D053961:Azabicyclo Compounds / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D003248:Constipation / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D005765:Gastrointestinal Agents / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use; D005769:Gastrointestinal Motility / Q000187:drug effects* / Q000502:physiology; D005772:Gastrointestinal Transit / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D007422:Intestines / Q000187:drug effects / Q000502:physiology; D008297:Male; D008875:Middle Aged; D010919:Placebos / Q000627:therapeutic use; D011247:Pregnancy; D055815:Young Adult
D053961:Azabicyclo Compounds; D005765:Gastrointestinal Agents; D010919:Placebos; C533727:TD-5108
Gastroenterology. 1978 Apr;74(4):698-703
631507
Am J Gastroenterol. 2005 Feb;100(2):362-72
15667494
Gut. 1999 May;44(5):682-6
10205205
J Nucl Med. 1997 Nov;38(11):1807-10
9374360
Clin Gastroenterol Hepatol. 2004 Sep;2(9):796-805
15354280
N Engl J Med. 2008 May 29;358(22):2344-54
18509121
Aliment Pharmacol Ther. 2002 Oct;16(10):1781-90
12269971
Gastroenterology. 1993 Oct;105(4):988-98
8405884
Br J Pharmacol. 2009 Jan;156(2):362-76
19154432
Scand J Gastroenterol. 1997 Sep;32(9):920-4
9299672
Dig Dis Sci. 1991 May;36(5):609-15
2022162
Gastroenterology. 2007 Sep;133(3):761-8
17854590
Neurogastroenterol Motil. 2007 Jan;19(1):30-8
17187586
Gastroenterology. 1992 Jul;103(1):36-42
1612355
Gastroenterology. 2001 Feb;120(2):354-60
11159875
Neurogastroenterol Motil. 2005 Dec;17(6):821-6
16336497
Aliment Pharmacol Ther. 2001 Nov;15(11):1745-51
11683688
Mayo Clin Proc. 1990 Nov;65(11):1456-79
2232900
N Engl J Med. 2003 Oct 2;349(14):1360-8
14523145
Am J Physiol Gastrointest Liver Physiol. 2006 May;290(5):G942-7
16603730
Br J Pharmacol. 2004 Nov;143(5):549-60
15466450
Am J Physiol. 1989 Aug;257(2 Pt 1):G284-90
2764112